Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate

References

• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.
   PubMed Web of Science ®Google Scholar
• Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, et al. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology. 2013 Sep;38(10):2003–10. doi:10.1038/npp.2013.99.
   PubMed Web of Science ®Google Scholar
• Brewer DD, Catalano RF, Haggerty K, Gainey RR, Fleming CB. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction. 1998 Jan;93(1):73–92. doi:10.1046/j.1360-0443.1998.931738.x.
   PubMed Web of Science ®Google Scholar
• Clarke TK, Crist RC, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, et al. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J. 2014 Jun;14(3):303–08. doi:10.1038/tpj.2013.30.
   PubMed Web of Science ®Google Scholar
• Senbanjo R, Wolff K, Marshall EJ, Strang J. Persistence of heroin use despite methadone treatment: poor coping self-efficacy predicts continued heroin use. Drug Alcohol Rev. 2009 Nov;28(6):608–15. doi:10.1111/j.1465-3362.2009.00064.x.
   PubMed Web of Science ®Google Scholar
• Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. Jama. 2004 Apr 21;291(15):1887–96. doi:10.1001/jama.291.15.1887.
   PubMed Web of Science ®Google Scholar
• Iribarne C, Picart D, Dreano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997;60(22):1953–64. doi:10.1016/S0024-3205(97)00160-4.
   PubMed Web of Science ®Google Scholar
• Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, Foltz RL. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem. 2002 Jul 1;306(1):31–39. doi:10.1006/abio.2002.5673.
   PubMed Web of Science ®Google Scholar
• Picard N, Cresteil T, Djebli N, Marquet P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689–95. doi:10.1124/dmd.105.003681.
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M, Eap C. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006 Dec;80(6):668–81. doi:10.1016/j.clpt.2006.09.012.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Stubbert K. Role of cytochrome P4502B6 in methadone metabolism and clearance. J Clin Pharmacol. 2013 Mar;53(3):305–13. doi:10.1002/jcph.1.
   PubMed Web of Science ®Google Scholar
• Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology. 2008 Mar;108(3):363–74. doi:10.1097/ALN.0b013e3181642938.
   PubMed Web of Science ®Google Scholar
• Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004 Jan;16(1):36–44. doi:10.1002/(ISSN)1520-636X.
   PubMed Web of Science ®Google Scholar
• Lee HY, Li JH, Sheu YL, Tang HP, Chang WC, Tang TC, Yeh Y-C, Wang S-Y, Liu R-H. Moving toward personalized medicine in the methadone maintenance treatment program: a pilot study on the evaluation of treatment responses in Taiwan. Biomed Res Int. 2013;2013:741403. doi:10.1155/2013/741403.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Regina KJ, Blood J, Friedel C. Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism. Anesthesiology. 2015 Nov;123(5):1142–53. doi:10.1097/ALN.0000000000000867.
   PubMed Web of Science ®Google Scholar
• Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol. 2013 Jul;18(4):709–16. doi:10.1111/j.1369-1600.2011.00349.x.
   PubMed Web of Science ®Google Scholar
• Tsai HJ, Wang SC, Liu SW, Ho IK, Chang YS, Tsai YT, Lin K-M, Liu Y-L. Assessment of CYP450 genetic variability effect on methadone dose and tolerance. Pharmacogenomics. 2014 May;15(7):977–86. doi:10.2217/pgs.14.19.
   PubMed Web of Science ®Google Scholar
• Wang SC, Ho IK, Tsou HH, Liu SW, Hsiao CF, Chen CH, Tan HK-L, Lin L, Wu C-S, Su L-W, et al. Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort. Omics. 2013 Oct;17(10):519–26. doi:10.1089/omi.2012.0068.
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, Monnat M, Huttemann H, Baumann P, Eap C. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005 Dec;78(6):593–604. doi:10.1016/j.clpt.2005.08.011.
   PubMed Web of Science ®Google Scholar
• Chen CH, Wang SC, Tsou HH, Ho IK, Tian JN, Yu CJ, Hsiao C-F, Chou S-Y, Lin Y-F, Fang K-C, et al. Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients. Pharmacogenomics. 2011 Oct;12(10):1397–406. doi:10.2217/pgs.11.103.
   PubMed Web of Science ®Google Scholar
• Oneda B, Crettol S, Bochud M, Besson J, Croquette-Krokar M, Hammig R, Monnat M, Preisig M, Eap CB. beta-Arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J. 2011 Aug;11(4):258–66. doi:10.1038/tpj.2010.37.
   PubMed Web of Science ®Google Scholar
• Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci. 2004;27:107–44. doi:10.1146/annurev.neuro.27.070203.144206.
   PubMed Web of Science ®Google Scholar
• Fujita W, Gomes I, Devi LA. Mu-Delta opioid receptor heteromers: new pharmacology and novel therapeutic possibilities. Br J Pharmacol. 2015 Jan;172(2):375–87. doi:10.1111/bph.12663.
   PubMed Web of Science ®Google Scholar
• Crettol S, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M, Déglon -J-J, Preisig M, Eap CB. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Oct 1;32(7):1722–27. doi:10.1016/j.pnpbp.2008.07.009.
   PubMed Web of Science ®Google Scholar
• Kolpe M, Carlson GA. Influence of attention-deficit/hyperactivity disorder symptoms on methadone treatment outcome. Am J Addict. 2007 Jan-Feb;16(1):46–48. doi:10.1080/10601330601080073.
   PubMed Web of Science ®Google Scholar
• Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, Doraimani G, et al. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013 Feb 01;128(1–2):71–76. doi:10.1016/j.drugalcdep.2012.08.002.
   PubMed Web of Science ®Google Scholar
• Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014 Jan;109(1):79–87. doi:10.1111/add.2014.109.issue-1.
   PubMed Web of Science ®Google Scholar
• Cao J, Hudziak JJ, Li D. Multi-cultural association of the serotonin transporter gene (SLC6A4) with substance use disorder. Neuropsychopharmacology. 2013 Aug;38(9):1737–47. doi:10.1038/npp.2013.73.
   PubMed Web of Science ®Google Scholar
• Muller CP, Homberg JR. The role of serotonin in drug use and addiction. Behav Brain Res. 2015 Jan 15;277:146–92. doi:10.1016/j.bbr.2014.04.007.
   PubMed Web of Science ®Google Scholar
• Lin SH, Chen KC, Lee SY, Yao WJ, Chiu NT, Lee IH, Chen PS, et al. The association between availability of serotonin transporters and time to relapse in heroin users: a two-isotope SPECT small sample pilot study. Eur Neuropsychopharmacol. 2012 Sep;22(9):647–50.
   PubMed Web of Science ®Google Scholar
• Yeh TL, Chen KC, Lin SH, Lee IH, Chen PS, Yao WJ, Lee S-Y, Yang YK, Lu R-B, Liao M-H, et al. Availability of dopamine and serotonin transporters in opioid-dependent users–a two-isotope SPECT study. Psychopharmacology (Berl). 2012 Mar;220(1):55–64. doi:10.1007/s00213-011-2454-6.
   PubMed Web of Science ®Google Scholar
• Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005 Oct;95(4):434–41. doi:10.1093/bja/aei210.
   PubMed Web of Science ®Google Scholar
• Dreifuss JA, Griffin ML, Frost K, Fitzmaurice GM, Potter JS, Fiellin DA, Selzer J, Hatch-Maillette M, Sonne SC, Weiss RD. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: results from a multisite study. Drug Alcohol Depend. 2013 Jul 1;131(1–2):112–18. doi:10.1016/j.drugalcdep.2012.12.010.
   PubMed Web of Science ®Google Scholar
• Gray AM. The effect of fluvoxamine and sertraline on the opioid withdrawal syndrome: a combined in vivo cerebral microdialysis and behavioural study. Eur Neuropsychopharmacol. 2002 Jun;12(3):245–54. doi:10.1016/S0924-977X(02)00028-7.
   PubMed Web of Science ®Google Scholar
• Harris GC, Aston-Jones G. Augmented accumbal serotonin levels decrease the preference for a morphine associated environment during withdrawal. Neuropsychopharmacology. 2001 Jan;24(1):75–85. doi:10.1016/S0893-133X(00)00184-6.
   PubMed Web of Science ®Google Scholar
• Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998 Nov;3(6):508–11. doi:10.1038/sj.mp.4000425.
   PubMed Web of Science ®Google Scholar
• Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007 Mar;12(3):247–57. doi:10.1038/sj.mp.4001926.
   PubMed Web of Science ®Google Scholar
• Farrell SM, Tunbridge EM, Braeutigam S, Harrison PJ. COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol Psychiatry. 2012 Mar 15;71(6):538–44. doi:10.1016/j.biopsych.2011.12.023.
   PubMed Web of Science ®Google Scholar
• Blasi G, Mattay VS, Bertolino A, Elvevag B, Callicott JH, Das S, Kolachana BS, et al. Effect of catechol-O-methyltransferase val158met genotype on attentional control. J Neurosci. 2005 May 18;25(20):5038–45. doi:10.1523/JNEUROSCI.0476-05.2005.
   PubMed Web of Science ®Google Scholar
• Wichers M, Aguilera M, Kenis G, Krabbendam L, Myin-Germeys I, Jacobs N, Peeters F, Derom C, Vlietinck R, Mengelers R, et al. The catechol-O-methyl transferase Val158Met polymorphism and experience of reward in the flow of daily life. Neuropsychopharmacology. 2008 Dec;33(13):3030–36. doi:10.1038/sj.npp.1301520.
   PubMed Web of Science ®Google Scholar
• Gatt JM, Burton KL, Williams LM, Schofield PR. Specific and common genes implicated across major mental disorders: a review of meta-analysis studies. J Psychiatr Res. 2015 Jan;60:1–13. doi:10.1016/j.jpsychires.2014.09.014.
   PubMed Web of Science ®Google Scholar
• Su H, Li Z, Du J, Jiang H, Chen Z, Sun H, Zhao M. Predictors of heroin relapse: personality traits, impulsivity, COMT gene Val158met polymorphism in a 5-year prospective study in Shanghai, China. Am J Med Genet B Neuropsychiatr Genet. 2015 Dec;168(8):712–19. doi:10.1002/ajmg.b.32376.
   PubMed Web of Science ®Google Scholar